ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1)

ClinicalTrials.gov ID: NCT00308139

Public ClinicalTrials.gov record NCT00308139. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 17, 2026, 6:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Open-Label, Multicenter, Comparator-Controlled Study to Examine the Effects of Exenatide Long-Acting Release on Glucose Control (HbA1c) and Safety in Subjects With Type 2 Diabetes Mellitus Managed With Diet Modification and Exercise and/or Oral Antidiabetic Medications

Study identification

NCT ID
NCT00308139
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
AstraZeneca
Industry
Enrollment
303 participants

Conditions and interventions

Interventions

  • exenatide Drug
  • exenatide, long acting release Drug

Drug

Eligibility (public fields only)

Age range
16 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 31, 2006
Primary completion
Jun 30, 2008
Completion
Jul 31, 2014
Last update posted
Aug 25, 2015

2006 – 2014

United States locations

U.S. sites
24
U.S. states
18
U.S. cities
24
Facility City State ZIP Site status
Research Site 182 Encino California 91436
Research Site 171 La Jolla California 92037
Research Site 518 San Diego California 92161
Research Site 024 Walnut Creek California 94598
Research Site Colorado Springs Colorado
Research Site 057 Miami Florida 33156
Research Site Chicago Illinois
Research Site 149 Indianapolis Indiana 46254
Research Site 099 Lexington Kentucky 40503
Research Site 017 Detroit Michigan 48202
Research Site 224 Minneapolis Minnesota 55416
Research Site 312 St Louis Missouri 63141
Research Site 023 Butte Montana 59701
Research Site 053 Rochester New York 14609
Research Site 002 Durham North Carolina 27713
Research Site 123 Winston-Salem North Carolina 27103
Research Site 405 Cincinnati Ohio 45219
Research Site 557 Marion Ohio 43302
Research Site 231 Portland Oregon 97239
Research Site 152 Philadelphia Pennsylvania 19146
Research Site 587 Greer South Carolina 29651
Research Site 015 Dallas Texas 75230
Research Site 009 San Antonio Texas 78229
Research Site 108 Olympia Washington 98502

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00308139, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 25, 2015 · Synced May 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00308139 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →